Ultratech, Inc.
ULTRATECH INC (Form: 10-Q, Received: 04/30/2007 15:29:03)
Table of Contents

 
 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
(Mark One)
     
þ   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2007
     
o   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from            to
Commission File Number 0-22248
ULTRATECH, INC.
(Exact name of registrant as specified in its charter)
     
DELAWARE
(State or other jurisdiction of
incorporation or organization)
  94-3169580
(I.R.S. Employer Identification No.)
     
3050 Zanker Road, San Jose, California
(Address of principal executive offices)
  95134
(Zip Code)
Registrant’s telephone number, including area code (408) 321-8835
(Former name, former address and former fiscal year, if changed since last report.)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer o       Accelerated filer þ       Non-accelerated filer o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practical date:
     
Class
common stock, $.001 par value
  Outstanding as of April 24, 2007
23,231,782
 
 

 


 

ULTRATECH, INC.
INDEX
         
    3  
 
       
    3  
 
       
    3  
 
       
    4  
 
       
    5  
 
       
    6  
 
       
    13  
 
       
    19  
 
       
    20  
 
       
    20  
 
       
    20  
 
       
    21  
 
       
    29  
 
       
    29  
 
       
    29  
 
       
    29  
 
       
    29  
 
       
    30  
  EXHIBIT 31.1
  EXHIBIT 31.2
  EXHIBIT 32.1

2


Table of Contents

PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
ULTRATECH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
                 
    March 31,     December 31,  
(In thousands )   2007     2006*  
    (Unaudited)          
ASSETS
               
Current assets:
               
Cash and cash equivalents
  $ 35,495     $ 23,883  
Short-term investments
    54,733       54,207  
Accounts receivable, net
    26,599       18,054  
Inventories
    38,291       40,988  
Prepaid expenses and other current assets
    3,038       2,181  
 
           
Total current assets
    158,156       139,313  
 
               
Long-term investments
    38,289       48,328  
Equipment and leasehold improvements, net
    21,013       20,326  
Demonstration inventories
    4,524       4,717  
Other assets
    2,542       3,366  
 
           
 
               
Total assets
  $ 224,524     $ 216,050  
 
           
 
               
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
Current liabilities:
               
Notes payable
  $ 16,278     $ 6,974  
Accounts payable
    9,647       10,440  
Deferred product and services income
    4,518       2,950  
Other current liabilities
    15,454       13,998  
 
           
Total current liabilities
    45,897       34,362  
 
               
Other liabilities
    6,855       7,580  
 
               
Stockholders’ equity
    171,772       174,108  
 
           
 
               
Total liabilities and stockholders’ equity
  $ 224,524     $ 216,050  
 
           
 
*   The Balance Sheet as of December 31, 2006 has been derived from the audited financial statements at that date.
See accompanying notes to unaudited condensed consolidated financial statements

3


Table of Contents

ULTRATECH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
                 
    Three Months Ended  
    March 31,     April 1,  
(In thousands, except per share amounts)   2007     2006  
Net sales:
               
Products
  $ 23,507     $ 31,409  
Services
    3,861       3,535  
 
           
Total net sales
    27,368       34,944  
 
               
Cost of sales:
               
Cost of products sold
    14,460       19,116  
Cost of services
    2,108       2,171  
 
           
 
Total cost of sales
    16,568       21,287  
 
           
Gross profit
    10,800       13,657  
 
               
Operating expenses:
               
Research, development, and engineering
    5,964       6,153  
Selling, general, and administrative
    9,302       7,297  
 
           
 
Operating income (loss)
    (4,466 )     207  
 
               
Interest expense
    (333 )     (12 )
Interest and other income, net
    1,669       1,517  
 
           
 
               
Income (loss) before income tax
    (3,130 )     1,712  
Provision for income taxes
    115       130  
 
           
 
Net income (loss)
  $ (3,245 )   $ 1,582  
 
           
 
               
Net income (loss) per share — basic
  (0.14 )   $ 0.07  
Number of shares used in per share computations — basic
    23,285       23,830  
 
               
Net income (loss) per share — diluted
  (0.14 )   $ 0.06  
Number of shares used in per share computations — diluted
    23,285       25,127  
See accompanying notes to unaudited condensed consolidated financial statements

4


Table of Contents

ULTRATECH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
                 
    Three Months Ended  
    March 31,     April 1,  
(In thousands)   2007     2006  
Cash flows from operating activities:
               
Net income (loss)
  $ (3,245 )   $ 1,582  
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
               
Depreciation
    1,513       1,526  
Amortization
    150       316  
Accretion of asset retirement obligations
    37       6  
Loss on disposal of equipment
    4       6  
Stock-based compensation
    359       473  
Deferred income taxes
          56  
Changes in operating assets and liabilities:
               
Accounts receivable
    (8,545 )     (40 )
Inventories
    1,234       (1,642 )
Prepaid expenses and other current assets
    70       290  
Demonstration inventory
          (116 )
Other assets
    824       7  
Accounts payable
    (793 )     411  
Deferred product and services income
    1,568       1,380  
Other current liabilities
    1,483       1,303  
Other liabilities
    (762 )     (194 )
 
           
Net cash provided by (used in) operating activities
    (6,103 )     5,364  
 
           
 
               
Cash flows from investing activities:
               
Capital expenditures
    (687 )     (589 )
Purchase of investments
    (6,453 )     (14,493 )
Proceeds from sales and maturities of investments
    15,302       9,960  
 
           
Net cash provided by (used in) investing activities
    8,162       (5,122 )
 
           
 
               
Cash flows from financing activities:
               
Proceeds from notes payable
    9,628       5,931  
Repayment of notes payable
    (324 )     (6,129 )
Proceeds from issuance of common stock
    381       2,442  
Tax benefit from stock options
          21  
 
           
Net cash provided by financing activities
    9,685       2,265  
 
           
 
               
Net effect of exchange rate changes on cash and cash equivalents
    (132 )     (124 )
 
               
Net increase in cash and cash equivalents
    11,612       2,383  
 
               
Cash and cash equivalents at beginning of period
    23,883       36,344  
 
           
 
               
Cash and cash equivalents at end of period
  $ 35,495     $ 38,727  
 
           
 
Supplemental disclosures of cash flow information:
               
Other non-cash activities:
               
Systems transferred to inventory from equipment and other assets
  (1,463 )   (1,035 )
See accompanying notes to unaudited condensed consolidated financial statements

5


Table of Contents

Ultratech, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
March 31, 2007
(1) Description of Business
Ultratech, Inc. (referred to as “Ultratech,” the “Company” and “we”) develops, manufactures and markets photolithography and laser thermal processing equipment for manufacturers of integrated circuits and nanotechnology components located throughout North America, Europe, Japan, Taiwan and the rest of Asia.
We supply step-and-repeat photolithography systems based on one-to-one imaging technology. Within the integrated circuits industry, we target the market for advanced packaging applications. Within the nanotechnology industry, our target markets include thin film head magnetic recording devices, ink jet print heads, laser diodes and light emitting diodes (LEDs). Our laser thermal processing equipment is targeted at advanced annealing applications within the semiconductor industry.
In evaluating our business segments, we gave consideration to the Chief Executive Officer’s review of financial information and the organizational structure of our management. Based on this review, we concluded that, at the present time, resources are allocated and other financial decisions are made based on our consolidated financial information. Accordingly, we have determined that we operate in one business segment, which is the manufacture and distribution of capital equipment to manufacturers of integrated circuits and nanotechnology components.
(2) Basis of Presentation
We have prepared the unaudited condensed consolidated financial statements in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments, consisting of only normal recurring adjustments considered necessary for fair presentation, have been included.
Our fiscal period ends on the Saturday closest to month-end. All references to the quarter refer to our fiscal quarter. Our fiscal quarters covered by this report ended on March 31, 2007 and April 1, 2006.
Operating results for the three months ended March 31, 2007 are not necessarily indicative of the results that may be expected for the year ending December 31, 2007 or any future period.
USE OF ESTIMATES — The preparation of the financial statements and related disclosures in conformity with accounting principles generally accepted in the United States requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosure of contingent assets and liabilities at the date of the consolidated financial statements. By their nature, these estimates and judgments are subject to an inherent degree of uncertainty. On an ongoing basis, we evaluate our estimates, including those related to inventories, warranty obligations, purchase order commitments, asset retirement obligations, bad debts, estimated useful lives of fixed assets, asset impairment, income taxes, intangible assets, contingencies and litigation. We base our estimates on historical experience and on various other analyses and assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS — In September 2006, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 157, Fair Value Measurements (SFAS No. 157) , which replaces the different definitions of fair value in the accounting literature with a single definition. It defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. SFAS No. 157 is effective for fair-value measurements already required or permitted by other standards for financial statements issued for fiscal years beginning after November 15, 2007 and interim periods within those fiscal years, with earlier adoption encouraged. We are currently in the process of determining the impact, if any, of adopting the provisions of SFAS No. 157 on our results of operations or financial position.
In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities—Including an amendment of FASB Statement No. 115 (SFAS No. 159), provides companies with an option to report selected financial assets and liabilities at fair value. The objective of SFAS No. 159 is to reduce both the complexity in accounting for

6


Table of Contents

financial instruments and the volatility in earnings caused by measuring related assets and liabilities differently. SFAS No. 159 also establishes presentation and disclosure requirements designed to facilitate comparisons between companies that choose different measurement attributes for similar types of assets and liabilities. SFAS No. 159 is effective fiscal years beginning after November 15, 2007, with earlier adoption permitted. We are currently in the process of determining the impact of adopting the provisions of SFAS No. 159 on our results of operations or statement of financial position.
(3) Stock-Based Compensation
Stock-based compensation expense recognized under SFAS No. 123 (revised 2004), Share-Based Payment (SFAS No. 123R), for employees and directors and the effect on our Condensed Consolidated Statements of Operations were as follows:
                 
    Three months ended  
    March 31,     April 1,  
(In thousands)   2007     2006  
Cost of Sales
  $ 33     $ 32  
Research, development, and engineering
    78       46  
Selling, general and administrative expenses
    248       395  
 
           
Total stock-based compensation expense
    359       473  
Tax benefit related to stock-based compensation expense
           
 
           
Net effect on net loss
  $ 359     $ 473  
 
           
Effect on net loss per basic and diluted share
  $ 0.02     $ 0.02  
 
           
Compensation cost capitalized as part of inventory was immaterial during each of the three-month periods ended March 31, 2007 and April 1, 2006.
Our 1993 Stock Option Plan/Stock Issuance Plan, as amended, and our 1998 Supplemental Stock Option/Stock Issuance Plan, as amended, provide for the grant of qualified and non-qualified stock-based awards to our eligible employees, consultants and advisors and non-employee directors. We believe that such awards better align the interests of our employees with those of our shareholders. As of March 31, 2007, there were a total of 1.5 million shares reserved for future awards under these Plans.
We used the following weighted-average assumptions to estimate the fair value of our stock options granted during the three-month periods ended March 31, 2007 and April 1, 2006:
                 
    Three Months Ended
    March 31,   April 1,
    2007   2006
Expected life (in years)
    4.94       3.5  
Risk-free interest rate
    4.80 %     3.42 %
Volatility factor
    0.48       0.52  
Dividend yield
           
The weighted-average grant date fair value of options granted during the three-months ended March 31, 2007 was $5.68. No options were granted during the corresponding quarter of 2006. We issued a total of 33,000 shares of common stock in connection with employee options exercised during the first quarter of 2007 compared to 163,000 shares during the corresponding quarter of 2006. We did not recognize any income tax benefit from stock options during the three-month periods ended March 31, 2007 and April 1, 2006.

7


Table of Contents

The fair value of restricted stock units is based upon the closing trading price of our common stock on the date of grant. No restricted stock unit vested during the three-month period ended March 31, 2007 compared to 5,000 restricted stock units vested during the three-month period ended April 1, 2006.
(4) Net Income (Loss) Per Share
The following sets forth the computation of basic and diluted net income (loss) per share:
                 
Numerator:
               
Net income (loss)
  $ (3,245 )   $ 1,582  
Denominator:
               
Denominator for basic net income (loss) per share
    23,285       23,830  
Effect of dilutive employee stock options
          1,297  
 
           
Denominator for diluted net income per share
    23,285       25,127  
 
           
 
               
Net income (loss) per share — basic:
               
Net income (loss)
  (0.14 )   $ 0.07  
 
           
 
               
Net income (loss) per share — diluted:
               
Net income (loss)
  (0.14 )   $ 0.06  
 
           
For the three-month periods ended March 31, 2007 and April 1, 2006, options to purchase 5.9 million and 1.7 million shares of common stock, respectively, were excluded from the computation of diluted net loss per share, as the effect would have been anti-dilutive. In addition, for the three months ended March 31, 2007, restricted stock units for 0.1 million shares of common stock were excluded from the computation as well. Options and restricted stock units are anti-dilutive when we have a net loss or when the exercise price of the stock option is greater than the average market price of our common stock during the period.
(5) Inventories
Inventories consist of the following:
                 
    March 31,     December 31,  
(In thousands)   2007     2006  
Raw materials
  $ 18,067     $ 18,067  
Work-in-process
    16,865       9,952  
Finished products
    3,359       12,969  
 
           
 
  $ 38,291     $ 40,988  
 
           
(6) Notes Payable
We have a line of credit agreement with a brokerage firm. Under the terms of this agreement, we may borrow funds at a cost equal to the current Federal funds open rate plus 100 basis points (approximately 6.25% as of March 31, 2007). Certain of

8


Table of Contents

our cash, cash equivalents and investments secure borrowings outstanding under this facility, but we are not restricted in the use of those assets. Funds are advanced to us under this facility based on pre-determined advance rates on the cash and securities held by us in this brokerage account. This agreement has no set expiration date and there are no loan covenants, other than the aforementioned collateral requirement. As of March 31, 2007, $16.3 million was outstanding under this facility, with a related collateral requirement of approximately $21.7 million of our cash, cash equivalents and investments.
(7) Other Current Liabilities
Other current liabilities consist of the following:
                 
    March 31,     December 31,  
(In thousands)   2007     2006  
Salaries and benefits
  $ 3,994     $ 3,632  
Warranty accrual
    2,378       2,264  
Advance billings
    2,671       2,713  
Income taxes payable
    747       876  
Accrued taxes-other
    2,820       2,076  
Reserve for losses on purchase order commitments
    684       623  
Other
    2,160       1,814  
 
           
 
  $ 15,454     $ 13,998  
 
           
Warranty Accrual
We generally warrant our products for a period of 12 months for new products, or three months for refurbished products, from the date of customer acceptance for material and labor to repair the product; accordingly, an accrual for the estimated cost of the warranty is recorded at the time the product is shipped. Extended warranty terms, if granted, result in deferral of revenue equating to our standard pricing for similar service contracts. Recognition of the related warranty cost is deferred until product revenue is recognized. Factors that affect our warranty liability include the number of installed units, historical and anticipated rates of warranty claims, and cost per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. We believe our warranty accrual, as of March 31, 2007, will be sufficient to satisfy outstanding obligations as of that date. Changes in our warranty accrual are as follows:
                 
    Three Months Ended  
    March 31,     April 1,  
(In thousands)   2007     2006  
Balance, beginning of the period
  $ 2,264     $ 2,397  
Warranties issued during the period
    1,061       917  
Settlements made during the period
    (1,019 )     (1,118 )
Changes in liability for pre-existing warranties
    72       390  
 
           
Balance, end of the period
  $ 2,378     $ 2,586  
 
           
Deferred Services Revenue
We sell service contracts for which revenue is deferred and recognized ratably over the contract period for time based service contracts, or as service hours are delivered for contracts based on a purchased quantity of hours. Changes in our deferred service revenue are as follows:

9


Table of Contents

                 
    Three Months Ended  
    March 31,     April 1,  
(In thousands)   2007     2006  
Balance, beginning of the period
  $ 2,444     $ 1,970  
Service contracts sold during the period
    1,120       3,957  
Service contract revenue recognized during the period
    (1,269 )     (2,714 )
 
           
Balance, end of the period
  $ 2,295     $ 3,213  
 
           
(8) Other Liabilities
Other liabilities consist of the following:
                 
    March 31,     December 31,  
(In thousands)   2007     2006  
Deferred rent
  $ 2,625     $ 2,737  
Deferred compensation
    1,507       2,160  
Asset retirement obligation
    2,018       1,982  
Postretirement medical obligation
    705       701  
 
           
 
  $ 6,855     $ 7,580  
 
           
(9) Accumulated Other Comprehensive Loss
Accumulated other comprehensive loss is comprised of the following items, net of tax:
                 
    March 31,     December 31,  
(In thousands)   2007     2006  
Unrealized gains (losses) on:
               
Available-for-sale investments
  $ (585 )   $ (847 )
Foreign exchange forward contracts
          132  
Change in minimum postretirement medical obligation
    (188 )     (200 )
 
           
Accumulated other comprehensive loss at end of period
  $ (773 )   $ (915 )
 
           
(10) Exit Activities
Changes in our accrued severance and benefits charges are as follows:
                                 
    Balance at                     Balance at  
    December 31,                     March 31,  
(In thousands)   2006     Expenses     Payments     2007  
Severance and benefits (fiscal 2006)
  $ 918     $     $ (330 )   $ 588  
Severance and benefits (fiscal 2007)
          727       (480 )     247  
 
                       
Total
  $ 918     $ 727     $ (810 )   $ 835  
 
                       

10


Table of Contents

In the first quarter of 2007, as a continuing effort to reduce company-wide expenses since the fourth quarter of 2006, we eliminated an additional 26 full-time positions, 85% in the United States and 15% internationally. Pursuant to the provisions of FASB Statement No. 146, Accounting for Costs Associated with Exit or Disposal Activities , during the first quarter of 2007, we recorded severance and benefits charges totaling $0.7 million related to this plan. Out of this $0.7 million, $0.4 million was recorded as selling, general and administrative expenses, $0.2 million as cost of sales, and the remaining $0.1 million as research, development, and engineering expenses. As of March 31, 2007, the remaining balances of $0.6 million and $0.2 million related to severance and benefit payments incurred during the fourth quarter of 2006 and the first quarter of 2007, respectively, will be fully paid by the second quarter of 2008.
(11) Related-Party Transactions
During the first quarter of 2007, we had a total of $5.9 million of net sales to a customer whose officer is a member of our Board of Directors. As of March 31, 2007, we had $3.5 million of accounts receivable from this customer. In addition, in March 2007, we entered into a capital lease for our office equipment with a vendor whose officer is another member of our Board of Directors. In connection with the capital lease, we are obligated to pay monthly installment of $11,000 for 60 months.
(12) Stock Repurchase Program
In September 2005, our Board of Directors authorized the repurchase of up to $30.0 million of our common stock in the open market at the then prevailing market prices during the period commencing September 2005 through September 2007. Through March 31, 2007 we had repurchased 1.4 million shares of our common stock at a total purchase price of $20.0 million since September 2005. We did not repurchase any shares of our common stock during the quarter ended March 31, 2007.
(13) Employee Benefit Plans
Employee bonus plans
We currently sponsor an executive incentive bonus plan that distributes employee awards based on the achievement of predetermined targets. We did not record any expense under this bonus plan for the three-month period ended March 31, 2007 compared to $0.4 million for the three-month period ended April 1, 2006.
Employee savings and retirement plans
We sponsor a 401(k) employee salary deferral plan that allows voluntary contributions by all full-time employees of from 1% to 20% of their pretax earnings. Our contributions made to this plan were $0.1 million for each of the three-month periods ended March 31, 2007 and April 1, 2006, respectively. Our contributions, limited to a maximum of $2,000 per year per employee, generally become 20 percent vested at the end of an employee’s first year of service from the date of hire with us, and vest 20 percent per year of service thereafter until they become fully vested at the end of five years of service. We also sponsor an executive non-qualified deferred compensation plan (the “Plan”) that allows qualifying executives to defer current cash compensation. As of March 31, 2007, Plan assets, representing the cash surrender value of life insurance policies held by us and liabilities were approximately $1.5 million each, respectively, and were included in our Consolidated Balance Sheets under the captions “other assets” and “other liabilities.” In conjunction with this Plan, the related expense for both quarters ended March 31, 2007 and April 1, 2006 was immaterial.
Postretirement benefits
We have committed to providing lifetime post-retirement medical and dental benefits to the Chief Executive Officer and Chief Financial Officer and their spouses, commencing after retirement. These medical and dental benefits are similar to the

11


Table of Contents

benefits provided to all full-time employees while employed by us, except that we are paying the entire cost of the postretirement benefits. During the first quarter of 2007, we amended and restated the employment agreement with our Chief Financial Officer to provide him and his spouse retirement health benefits in the event of a change of control or sale of the Company or in the event that he retires when he is at least 62 years old and has served as an executive officer for 10 consecutive years. We recorded net periodic benefit costs of $13,000 and $11,000 for the quarters ended March 31, 2007 and April 1, 2006, respectively. These expenses included interest cost and amortization of prior service cost.
(14) Income Taxes
In accordance with the adoption of FASB Financial Interpretation Number (FIN) 48, Accounting for Uncertainty in Income Taxes (FIN 48), we have unrecognized tax benefits of $2.8 million as of January 1, 2007. We continue to recognize interest and penalties as a component of income tax expense and have accrued $55,000 for these items as of January 1, 2007. The implementation of FIN 48 as of January 1, 2007 resulted in a decrease of $20,000 to the liability for uncertain tax positions and a decrease to accumulated deficit of $27,000. All other adjustments required upon adoption of FIN 48 were to the deferred tax accounts with an offsetting adjustment to the valuation allowance.
If we are able to eventually recognize these uncertain tax positions, $2.5 million of the unrecognized benefit would reduce the effective tax rate. We currently have a full valuation allowance against our U.S. net deferred tax asset which would impact the timing of the effective tax rate benefit should any of these uncertain tax positions be favorably settled in the future. We anticipate an increase to the unrecognized tax benefits during fiscal 2007 applicable to research and development tax credits and foreign tax exposures. While the increase cannot be estimated at this time, the change is not expected to be material to the fiscal 2007 financial statements.
We are subject to federal and state tax examinations for years 1999 forward and 1997 forward, respectively, by virtue of the tax attributes carrying forward from those years. We are also subject to audits in the foreign jurisdictions in which we operate for years 2000 and forward. There are no tax examinations currently in progress.
(15) Contingencies
Legal Proceedings
On February 29, 2000, we filed lawsuits asserting patent infringement and related claims against Nikon, Canon and ASML in the U.S. District Court for the Eastern District of Virginia. In April 2000, we reached a settlement with Nikon, and in September 2001, we reached a settlement with Canon. In the patent litigation against ASML, after transfer to the U.S. District Court for the Northern District of California, a jury trial was conducted during the second quarter of 2005. The jury reached a verdict that the patent was infringed, but that the asserted claims of the patent were invalid. We filed a post-trial motion for a new trial and for judgment as a matter of law in our favor. ASML also filed a motion for judgment as a matter of law seeking to invalidate three of the asserted claims for lack of enablement and requested that the Court award costs. On February 13, 2006, the Court denied our post-trial motions, including the motion for a new trial, and entered judgment in favor of ASML invalidating three claims of the patent for lack of enablement. The Court also awarded ASML approximately $330,000 in costs. We have filed an appeal with the Federal Circuit Court of Appeals, and filed our opening appellate brief on August 31, 2006. Although ASML originally filed a notice of cross-appeal, ASML subsequently withdrew its cross appeal and the Court entered an order to that effect on December 8, 2006. ASML’s opening appellate brief was filed on December 6, 2006, and our reply brief was filed on January 12, 2007. The case is set for oral argument on May 11, 2007.
On July 11, 2003, we filed a lawsuit against a Southern California company asserting infringement of certain claims related to U.S. patent No. 5,621,813 in the U.S. District Court in and for the Northern District of California. On May 17, 2005, the court found the subject patent to be invalid. We appealed this decision. The defendant subsequently brought a motion for reimbursement of its attorneys’ fees and costs in a total asserted amount of approximately $2 million. We opposed this motion, and on October 12, 2005, the District Court denied the defendant’s request for attorneys’ fees in its entirety. The defendant appealed that decision. On November 3, 2005, the defendant filed a notice of appeal with respect to the court’s ruling on its motion for attorneys’ fees. In March 2006, the Federal Circuit court upheld the district court’s ruling that the subject patent is invalid. On August 8, 2006, the Federal Circuit court upheld the District Court’s denial of attorneys’ fees. Neither side appealed the rulings by the Federal Circuit, and they are final.

12


Table of Contents

In May 2006, the same company filed a state court lawsuit against us for malicious prosecution and abuse of process claiming that attorney’s fees, costs and other damages were due based on the outcome of a federal patent litigation suit brought against it by us. We do not believe this new action has merit, particularly given the denial by the federal court and the subsequent federal appellate court’s affirmation of the order denying the award of any attorney’s fees payable to this company by us in the federal patent litigation. We filed a motion to have the state court complaint dismissed under California’s anti-SLAPP and demurrer statutes. The state court granted the anti-SLAPP motion as to the abuse of process claim, but denied it as to the malicious prosecution claim. We have appealed the decision denying the anti-SLAPP motion as to the latter, and briefing thereon shall commence shortly.
On March 7, 2007, a shareholder filed a shareholder derivative lawsuit against us and certain of our current and former directors, officers and employees in the U.S. District Court for the Northern District of California. The lawsuit purports to be on behalf of Ultratech and asserts claims for violations of federal and state securities laws and for breach of fiduciary duty, unjust enrichment and other claims related to the alleged backdating of stock option grants between 1996 and 2003. On March 30, 2007, an essentially identical lawsuit was filed by another shareholder against us and certain of our current and former directors, officers and employees in the U.S. District Court for the Northern District of California. The complaints request an award of unspecified damages, an accounting of stock option grants, disgorgement of profits, rescission of option grants, equitable relief for alleged breach of fiduciary duty and awarding the plaintiff’s legal fees and expenses. As publicly reported in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2006, we proactively established a special committee of our Board of Directors comprised solely of independent directors to conduct a voluntary, company-initiated review of our historical stock option grants from Ultratech’s initial public offering in 1993 to July 2006. The special committee retained independent outside legal counsel to assist the committee with this review. The special committee completed its review and concluded there were no material accounting issues or backdating or other inappropriate manipulation regarding the issuance and pricing of stock options. Based on these findings, we have determined that no adjustments to previously filed financial statements are required.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Certain of the statements contained herein, which are not historical facts and which can generally be identified by words such as “anticipates”, “expects”, “intends”, “will”, “could”, “believes”, “estimates”, “continue”, and similar expressions, are forward-looking statements under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties, such as risks related to our dependence on new product introductions and market acceptance of new products and enhanced versions of our existing products; lengthy sales cycles, including the timing of system installations and acceptances; lengthy and costly development cycles for laser-processing and lithography technologies and applications; integration, development and associated expenses of the laser processing operation; delays, deferrals and cancellations of orders by customers; cyclicality in the semiconductor and nanotechnology industries; pricing pressures and product discounts; high degree of industry competition; intellectual property matters; expiration of licensing arrangements, and the resulting adverse impact on our licensing revenues; changes to financial accounting standards; changes in pricing by us, our competitors or suppliers; customer concentration; international sales; timing of new product announcements and releases by us or our competitors; ability to volume produce systems and meet customer requirements; sole or limited sources of supply; ability and resulting costs to attract or retain sufficient personnel to achieve our targets for a particular period; dilutive effect of employee stock option grants on net income per share, which is largely dependent upon us achieving and maintaining profitability and the market price of our stock; mix of products sold; rapid technological change and the importance of timely product introductions; outcome of litigation; manufacturing variances and production levels; timing and degree of success of technologies licensed to outside parties; product concentration and lack of product revenue diversification; inventory obsolescence; asset impairment; effects of certain anti-takeover provisions; announced and future acquisitions; volatility of stock price; foreign government regulations and restrictions; business interruptions due to natural disasters or utility failures; environmental regulations; and any adverse effects of terrorist attacks in the United States or elsewhere, or government responses thereto, or military actions in Iraq, Afghanistan, North Korea and elsewhere, on the economy in general, or on our business in particular. Due to these and additional factors, the statements, historical results and percentage relationships set forth below are not necessarily indicative of the results of operations for any future period. These forward-looking statements are based on management’s current beliefs and expectations, some or all of which may prove to be inaccurate, and which may change. We undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date of this report.

13


Table of Contents

OVERVIEW
We develop, manufacture and market photolithography and laser thermal processing equipment for manufacturers of integrated circuits and nanotechnology components located throughout North America, Europe, Japan, Taiwan and the rest of Asia.
We supply step-and-repeat photolithography systems based on one-to-one imaging technology. Within the integrated circuits industry, we target the market for advanced packaging applications. Within the nanotechnology industry, our target markets include thin film head magnetic recording devices, ink jet print heads, laser diodes and light emitting diodes (LEDs). Our laser thermal processing equipment is targeted at advanced annealing applications within the semiconductor industry.
RESULTS OF OPERATIONS
We derive a substantial portion of our total net sales from sales of a relatively small number of newly manufactured systems, which typically range in price from $1.2 million to $5.6 million. As a result of these high sale prices, the timing and recognition of revenue from a single transaction has had and most likely will continue to have a significant impact on our net sales and operating results for any particular period.
Our backlog at the beginning of a period typically does not include all of the sales needed to achieve our sales objectives for that period. In addition, orders in backlog are subject to cancellation, shipment or customer acceptance delays, and deferral or rescheduling by a customer with limited or no penalties. Consequently, our net sales and operating results for a period have been and will continue to depend on our obtaining orders for systems to be shipped and accepted in the same period in which the order is received. Our business and financial results for a particular period could be materially adversely affected if an anticipated order for even one system is not received in time to permit shipment and customer acceptance during that period. Furthermore, a substantial portion of our shipments has historically occurred near the end of the quarter. Delays in installation and customer acceptance due, for example, to our inability to successfully demonstrate the agreed-upon specifications or criteria at the customer’s facility, or to the failure of the customer to permit installation of the system in the agreed upon time, may cause net sales in a particular period to fall significantly below our expectations, which may materially adversely affect our operating results for that period. This risk is especially applicable in connection with the introduction and initial sales of a new product line. Additionally, the failure to receive anticipated orders or delays in shipments due, for example, to rescheduling, delays, deferrals or cancellations by customers, additional customer configuration requirements, or to unexpected manufacturing difficulties or delays in deliveries by suppliers due to their long production lead times or otherwise, have caused and may continue to cause net sales in a particular period to fall significantly below our expectations, materially adversely affecting our operating results for that period. In particular, the long manufacturing and acceptance cycles of our advanced packaging family of wafer steppers and laser thermal processing systems and the long lead time for lenses and other materials, could cause shipments and acceptances of such products to be delayed from one quarter to the next, which could materially adversely affect our financial condition and results of operations for a particular quarter.
Additionally, the need for continued expenditures for research and development, capital equipment, ongoing training and worldwide customer service and support, among other factors, will make it difficult for us to reduce our operating expenses in a particular period if we fail to achieve our net sales goals for the period.

14


Table of Contents

Net sales
                                 
    Three Months Ended              
    March 31,     April 1,     Amount of     Percentage  
(In millions)   2007     2006     Change     Change  
Sales of:
                               
Products
  $ 23.5     $ 31.4     (7.9 )     -25 %
Services
    3.9       3.5       0.4       11 %
 
                         
Total net sales
  $ 27.4     $ 34.9     (7.5 )     -21 %
 
                         
Net sales consist of revenues from products (system sales, spare parts sales and upgrades) and services. Product sales decreased 25% to $23.5 million primarily due to a system unit volume decrease of 36.4% in the first quarter of 2007, compared to $31.4 million in the first quarter of 2006. This system unit volume decrease is offset partially by an increase in average selling price. The average selling prices of systems sold increased 8.9% compared to the corresponding quarter of 2006, resulting from a continuing shift in product mix in favor of our new laser processing products and away from our legacy platform products.
On a product market application basis, system sales to the semiconductor industry, primarily for advanced packaging and laser processing applications, were $17.8 million for the quarter ended March 31, 2007, a decrease of 30.3% when compared with system sales of $25.5 million to this market in the corresponding quarter of 2006. This decrease was due to a $12.9 million decrease in sales to the advanced packaging markets offset by a increase of $4.6 million to the laser processing markets.
System sales to the nanotechnology market were $0.9 million for the quarter ended March 31, 2007, a decrease of 35.7% compared with sales of $1.4 million in the corresponding quarter of 2006. System sales to the nanotechnology market are highly dependent on customer capacity demand in the thin film head industry.
Revenues from services for the first quarter of 2007 were $3.9 million, an increase of 11.4% over the corresponding quarter of 2006, primarily as a result of an increase in service contracts.
At March 31, 2007, we had approximately $4.5 million of deferred product and services income compared to $3.0 million at December 31, 2006. Deferred income related to our products is recognized upon satisfying the contractual obligations for installation and/or customer acceptance. Deferred service revenue is recognized ratably over the contract period or as purchased services are rendered.
For the quarter ended March 31, 2007, international net sales were $20.8 million, or 76.3% of total net sales compared with $20.2 million, or 57.9% of total net sales for the first quarter of 2006. We expect sales to international customers will continue to represent a significant majority of our revenues during the remainder of 2007. Our revenue derived from sales in foreign countries is not generally subject to significant exchange rate fluctuations, principally because sales contracts for our systems are generally denominated in U.S. dollars. In Japan, however, orders are often denominated in Japanese yen. This subjects us to the risk of currency fluctuations. We attempt to mitigate this risk by entering into foreign currency forward exchange contracts for the period between when an order is received and when it is recorded as revenue. After recording revenue, we use various mechanisms, such as foreign currency forward exchange contracts and natural hedges, to offset substantial portions of the gains or losses associated with our Japanese yen denominated receivables due to exchange rate fluctuations. We had approximately $8.1 million of Japanese yen denominated receivables at March 31, 2007. International sales expose us to a number of additional risks, including fluctuations in the value of local currencies relative to the U.S. dollar, which impact the relative cost of ownership of our products and, thus, the customer’s willingness to purchase our product. (See “Item 1A Risk Factors: International Sales”).
Gross profit
On a comparative basis, gross margins were 39.5% and 39.1% for the first quarter of 2007 and 2006, respectively, which was primarily due to improved installation costs related to our new laser spike annealing systems compared to the corresponding quarter of 2006. We introduced our laser spike annealing systems to the market during December 2005.
Our gross profit as a percentage of sales has been and most likely will continue to be significantly affected by a variety of factors, including the introduction of new products, which typically have higher manufacturing costs until manufacturing efficiencies are realized and which are typically discounted more than existing products until the products gain market acceptance; the mix of products sold; the rate of capacity utilization; write-down of inventory and open purchase commitments; product discounts, pricing and competition in our targeted markets; non-linearity of shipments during the

15


Table of Contents

quarter which can result in manufacturing inefficiencies; the percentage of international sales, which typically have lower gross margins than domestic sales principally due to higher field service and support costs; and start-up costs and inefficiencies associated with the implementation of subcontracting arrangements.
Operating expenses
Research, development and engineering expenses for the first quarter of 2007 were $6.0 million, as compared to $6.2 million for the same period in 2006. The decrease was primarily due to the transfer of some engineers to manufacturing, which was partially offset by $0.1 million severance and benefit charges in connection with our continuing effort to reduce company-wide expenses.
Selling, general, and administrative expenses were $9.3 million for the first quarter of 2007, as compared with $7.3 million for the same quarter of 2006. As a percentage of net sales, selling, general, and administrative expenses increased to 34.0% in the quarter ended March 31, 2007, compared to 20.9% in the same quarter of 2006. This increase was primarily due to an increase in customer service expenses of $0.7 million primarily due to customer support services provided, severance and benefit charges of $0.4 million in connection with our continuing effort to reduce company-wide expenses, additional accounting-related fees of $0.7 million and legal fees of $0.3 million.
Interest and other income, net
Interest and other income, net, which consists primarily of interest income, was $1.7 million for the first quarter of 2007 as compared with $1.5 million for the comparable period of 2006. This increase was primarily attributable to a gain from foreign currency exchange resulting from a hedge recognized during the first quarter of 2007, which was partially offset by lower interest income due to lower cash and investment balances during the first quarter of 2007 compared to the same quarter of 2006. We presently maintain an investment portfolio with a weighted-average maturity of approximately 1.1 years. As a result, changes in short-term interest rates have had, and will continue to have, a significant impact on our interest income.
Provision for income taxes
For each of the three months ended March 31, 2007 and April 1, 2006, we recorded an income tax provision of $0.1 million. The income tax provision recognized for the three months ended March 31, 2007 primarily resulted from the foreign income taxes applicable to our forecast of foreign pre-tax income expected for the year. Since we are currently operating at a loss on a consolidated basis, there are no U.S. federal or state taxes anticipated for the year. The tax provision recognized in the first quarter of 2006 resulted from our then-forecasted foreign income taxes and U.S. federal alternative minimum tax for the year ended December 31, 2006.
Income tax estimates can be affected by whether or not, and within which jurisdictions, future earnings will occur and how and when cash is repatriated to the United States, combined with other aspects of an overall income tax strategy. Additionally, taxing jurisdictions could retroactively disagree with our tax treatment of certain items, and some historical transactions have income tax effects going forward. Accounting rules require these future effects to be evaluated using current laws, rules and regulations, each of which can change at any time and in an unpredictable manner. We believe we have adequately provided for any reasonably foreseeable outcome related to these matters, and we do not anticipate any material earnings impact from their ultimate resolutions.
Each quarter we assess the likelihood that we will be able to recover our deferred tax assets. We consider all available evidence, both positive and negative, including historical levels of income, expectations and risks associated with estimates of future taxable income and ongoing prudent and feasible tax planning strategies in assessing the need for the valuation allowance. As a result of our analysis of all available evidence, we concluded that it is more likely than not that our net deferred tax assets will not be realized, with the exception of the Japan and Taiwan deferred tax assets which we do expect to realize and have been recorded in the accounts. Therefore, we continue to provide a full valuation allowance against net deferred tax assets outside of Japan and Taiwan. We closely monitor all available evidence, and may release some or all of the valuation allowance in future periods.
In accordance with the adoption of FASB Financial Interpretation Number (FIN) 48, Accounting for Uncertainty in Income Taxes (FIN 48) effective January 1, 2007, we have unrecognized tax benefits of $2.8 million as of January 1, 2007. We continue to recognize interest and penalties as a component of income tax expense and have accrued $55,000 for these items as of January 1, 2007. The implementation of FIN 48 resulted in a decrease of $20,000 to the liability for uncertain tax positions and a decrease to accumulated deficit of $27,000. All other adjustments required upon adoption of FIN 48 were to the deferred tax accounts with an offsetting adjustment to the valuation allowance.

16


Table of Contents

If we are able to eventually recognize these uncertain tax positions, $2.5 million of the unrecognized benefit would reduce the effective tax rate. We currently have a full valuation allowance against our U.S. net deferred tax asset which would impact the timing of the effective tax rate benefit should any of these uncertain tax positions be favorably settled in the future. We anticipate an increase to the unrecognized tax benefits during fiscal 2007 applicable to research and development tax credits and foreign tax exposures. While the increase cannot be estimated at this time, the change is not expected to be material to the fiscal 2007 financial statements.
We are subject to federal and state tax examination for years 1999 forward and 1997 forward, respectively, by virtue of the tax attributes carrying forward from those years. We are also subject to audits in the foreign jurisdictions in which we operate for years 2000 and forward. There are no tax examinations currently in progress.
Outlook
The anticipated timing of orders, shipments and customer acceptances usually requires us to fill a number of production slots in any given quarter in order to meet our sales targets. If we are unsuccessful in our efforts to secure those production orders, or if existing production orders are delayed or cancelled, our results of operations will be materially adversely impacted. Accordingly, we may not be able to achieve or maintain our current or prior level of sales. We presently expect that net sales for the second quarter of 2007 to increase slightly from the net sales reported in first quarter of 2007. For the full year of 2007, we believe total net sales will increase 5% to 10% from the amount reported in 2006 .
Because our net sales are subject to a number of risks, including risks associated with the market acceptance of our new laser processing product line, delays in customer acceptances, intense competition in the capital equipment industry, uncertainty relating to the timing and market acceptance of our products, and the condition of the macro-economy and the semiconductor industry and the other risks described in this report and in our Annual Report on Form 10-K for the year ended December 31, 2006, we may not exceed or maintain our current or prior level of net sales for any period in the future. Additionally, we believe that the market acceptance and volume production of our advanced packaging systems, laser processing systems and our 1000 series family of wafer steppers are of critical importance to our future financial results. At March 31, 2007, these critical systems represented approximately 83% of our backlog. To the extent that these products do not achieve or maintain significant sales due to difficulties involving manufacturing or engineering, the inability to reduce the current long manufacturing cycles for these products, competition, excess capacity in the semiconductor or nanotechnology device industries, or any other reason, our business, financial condition and results of operations would be materially adversely affected.
We believe that gross margin for the second quarter of 2007 will increase due to product mix for the quarter and continued cost cutting efforts in manufacturing. The final gross margin achieved will depend heavily upon sales volumes and the resulting product mix. Should our sales not reach the level expected, we may incur a higher risk of inventory obsolescence and excess purchase commitments and lower utilization of our manufacturing infrastructure, which would materially adversely impact our results of operations. New products generally have lower gross margins until there is widespread market acceptance and until production and after-sales efficiencies can be achieved. Should significant market demand fail to develop for our laser processing systems and our new advanced packaging offerings, our business, financial condition and results of operations would be materially adversely affected. In addition, higher costs associated with extended manufacturing and customer acceptance periods on shipments of our new laser processing products have had, and will continue to have, an adverse impact on our gross margins. We anticipate operating expenses for the second quarter of 2007 to remain approximately the same as the first quarter of 2007 on an absolute dollar basis. For the full year of 2007, we believe our operating cash flow will be positive and our operating income will be close to breakeven.
LIQUIDITY AND CAPITAL RESOURCES
Net cash used in operating activities was $6.1 million for the three months ended March 31, 2007, compared with net cash provided by operating activities of $5.4 million for the comparable period in 2006. Net cash used in operating activities during the first three months of 2007 was primarily attributable to a net loss of $3.2 million for the first quarter of 2007 and an increase in accounts receivable of $8.6 million, which was partially offset by non-cash charges to net loss, principally for depreciation, amortization and stock-based compensation of $2.0 million, a decrease in deferred product and services income of $1.6 million and a decrease in inventories of $1.2 million.

17


Table of Contents

We believe that because of the relatively long manufacturing cycle of certain of our systems, particularly newer products, our inventories will continue to represent a significant and growing portion of working capital. Currently, we are devoting significant resources to the development, introduction and commercialization of our laser processing system and to the development of our next generation 1X lithography technologies. We currently intend to continue to incur significant operating expenses in the areas of research, development and engineering, manufacturing, and selling, general and administrative costs in order to further develop, produce and support these new products. Additionally, gross profit margins, inventory and capital equipment levels may be adversely impacted in the future by costs associated with the initial production of the laser processing system and by future generations of our 1X wafer steppers. These costs include, but are not limited to, additional manufacturing overhead, costs of demonstration systems and facilities and the establishment of additional after-sales support organizations. Additionally, there can be no assurance that operating expenses will not increase, relative to sales, as a result of adding technical, marketing and administrative personnel, among other costs, to support our new products. If we are unable to achieve significantly increased net sales or if our sales fall below expectations, our cash flow and operating results will be materially adversely affected until, among other factors, costs and expenses can be reduced. Our failure to achieve our sales targets for these new products could result in additional inventory write-offs and asset impairment charges, either or both of which could materially adversely impact our results of operations.
During the first three months of 2007, net cash provided by investing activities was $8.2 million, attributable to net proceeds of short and long-term investments of $8.9 million, offset by capital expenditures of $0.7 million.
Net cash provided by financing activities was $9.7 million during the first three months of 2007, attributable to net proceeds under our notes payable of $9.3 million and $0.4 million of proceeds received from the issuance of common stock under our employee stock option plans.
At March 31, 2007, we had working capital of $112.3 million and long-term investments of $38.3 million. Our principal sources of liquidity at March 31, 2007 consisted of $74.0 million in cash, cash equivalents and short-term investments, net of outstanding borrowings under our line of credit, and $38.3 million of long-term investments. We have a line of credit agreement with a brokerage firm. Under the terms of this agreement, we may borrow funds at a cost equal to the current Federal funds open rate plus 100 basis points (approximately 6.25% as of March 31, 2007). Certain of our cash, cash equivalents and marketable securities secure borrowings outstanding under this facility, but we are not restricted in the use of those assets. Funds are advanced to us under this facility in accordance with pre-determined advance rates based on the cash and securities held by us in this brokerage account. This agreement has no set expiration date and there are no loan covenants other than a collateral requirement. As of March 31, 2007, $16.3 million was outstanding under this facility, with a related collateral requirement of approximately $21.7 million of our cash, cash equivalents and investments.
In September 2005, our Board of Directors authorized the repurchase of up to $30.0 million of our common stock in the open market at then prevailing market prices during the period commencing September 2005 through September 2007. Through March 31, 2007, we had repurchased 1.4 million shares of our common stock at a total purchase price of $20.0 million. We did not repurchase any shares of our common stock during the quarter ended March 31, 2007. Any future repurchase of stock could have a significant impact on our cash position.
The development and manufacture of new lithography and laser-based systems and enhancements are highly capital-intensive. In order to be competitive, we believe we must continue to make significant expenditures for capital equipment; sales, service, training and support capabilities; systems, procedures and controls; and expansion of operations and research and development, among many other items. We expect that cash generated from operations and our cash, cash equivalents and short-term investments will be sufficient to meet our cash requirements for at least the next twelve months. However, in the near-term, we may continue to utilize existing and future lines of credit, and other sources of financing, in order to maintain our present levels of cash, cash equivalents and investments. Beyond the next twelve months, we may require additional equity or debt financing to address our working capital or capital equipment needs. In addition, we may seek to raise equity or debt capital at any time that we deem market conditions to be favorable. Additional financing, if needed, may not be available on reasonable terms, or at all.
We may in the future pursue acquisitions of complementary product lines, technologies or businesses. Future acquisitions may result in potentially dilutive issuances of equity securities, the incurrence of debt and contingent liabilities and amortization expenses and impairment charges related to goodwill and other intangible assets, which could materially adversely affect our financial condition and results of operations. In addition, acquisitions involve numerous risks, including difficulties in the assimilation of the operations, technologies, personnel and products of the acquired companies; the

18


Table of Contents

diversion of management’s attention from other business concerns; risks of entering markets in which we have limited or no direct experience; and the potential loss of key employees of the acquired company. In the event we acquire product lines, technologies or businesses which do not complement our business, or which otherwise do not enhance our sales or operating results, we may incur substantial write-offs and higher recurring operating costs, which could have a material adverse effect on our business, financial condition and results of operations. In the event that any such acquisition does occur, there can be no assurance as to the effect thereof on our business or operating results.
Foreign Currency
As part of our overall strategy to manage the level of exposure to the risk of foreign currency exchange rate fluctuations, we attempt to hedge most of our Japanese yen denominated foreign currency exposures. We use foreign currency forward contracts to hedge the risk that outstanding Japanese yen denominated receipts from customers, for actual or forecasted sales of equipment after receipt of customer orders, may be adversely affected by changes in foreign currency exchange rates. We use foreign currency forward exchange contracts and natural hedges to offset substantial portions of the potential gains or losses associated with our Japanese yen denominated assets and liabilities due to exchange rate fluctuations. We enter into foreign currency forward contracts that generally have maturities of nine months or less.
Information Available on Company Website
Our website is located at www.ultratech.com . We make available, free of charge through our website, our annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K (and amendments to those reports), as soon as reasonably practicable after such reports are filed electronically with the SEC. We have adopted a Code of Ethics for our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We have posted this Code of Ethics on our website. Any future amendments to this Code will also be posted on our website.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Reference is made to Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K for the year ended December 31, 2006 and to the subheading “Derivative Instruments and Hedging” in Item 8, “Financial Statements and Supplementary Data”, under the heading “Notes to Consolidated Financial Statements” of our Annual Report on Form 10-K for the year ended December 31, 2006.
Interest Rate Risk
Our exposure to market risk due to potential changes in interest rates relates primarily to our investment portfolio, which consisted primarily of fixed interest rate instruments as of March 31, 2007. We maintain an investment policy designed to ensure the safety and preservation of our invested funds by limiting market risk and the risk of default.
Certain of our cash, cash equivalents and short and long-term investments serve as collateral for a line of credit we maintain with a brokerage firm. The line of credit is used for liquidity purposes, mitigating the need to liquidate investments in order to meet our current operating cash requirements.
Foreign Currency Risk Management
The majority of our revenue, expense and capital purchasing activities are transacted in U.S. dollars. However, we do enter into these transactions in other currencies, primarily Japanese yen. To protect against reductions in value and the volatility of future cash flows caused by changes in currency exchange rates, we have established cash flow and balance sheet hedging programs.
We use foreign currency forward contracts to hedge the risk that outstanding Japanese yen denominated receipts from customers for actual or forecasted sales of equipment may be adversely affected by changes in foreign currency exchange rates. Our hedging programs reduce, but do not always entirely eliminate, the impact of currency movements.

19


Table of Contents

Item 4. Controls and Procedures
We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this report (the “Evaluation Date”). Based upon the evaluation, our principal executive officer and principal financial officer concluded that, as of the Evaluation Date, our disclosure controls and procedures were effective and ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms. Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to management to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Management is further required to apply judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended March 31, 2007 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
On February 29, 2000, we filed lawsuits asserting patent infringement and related claims against Nikon, Canon and ASML in the U.S. District Court for the Eastern District of Virginia. In April 2000, we reached a settlement with Nikon, and in September 2001, we reached a settlement with Canon. In the patent litigation against ASML, after transfer to the U.S. District Court for the Northern District of California, a jury trial was conducted during the second quarter of 2005. The jury reached a verdict that the patent was infringed, but that the asserted claims of the patent were invalid. We filed a post-trial motion for a new trial and for judgment as a matter of law in our favor. ASML also filed a motion for judgment as a matter of law seeking to invalidate three of the asserted claims for lack of enablement and requested that the Court award costs. On February 13, 2006, the Court denied our post-trial motions, including the motion for a new trial, and entered judgment in favor of ASML invalidating three claims of the patent for lack of enablement. The Court also awarded ASML approximately $330,000 in costs. We have filed an appeal with the Federal Circuit Court of Appeals, and filed our opening appellate brief on August 31, 2006. Although ASML originally filed a notice of cross-appeal, ASML subsequently withdrew its cross appeal and the Court entered an order to that effect on December 8, 2006. ASML’s opening appellate brief was filed on December 6, 2006, and our reply brief was filed on January 12, 2007. The case is set for oral argument on May 11, 2007.
On July 11, 2003, we filed a lawsuit against a Southern California company asserting infringement of certain claims related to U.S. patent No. 5,621,813 in the U.S. District Court in and for the Northern District of California. On May 17, 2005, the court found the subject patent to be invalid. We appealed this decision. The defendant subsequently brought a motion for reimbursement of its attorneys’ fees and costs in a total asserted amount of approximately $2 million. We opposed this motion, and on October 12, 2005, the District Court denied the defendant’s request for attorneys’ fees in its entirety. The defendant appealed that decision. On November 3, 2005, the defendant filed a notice of appeal with respect to the court’s ruling on its motion for attorneys’ fees. In March 2006, the Federal Circuit court upheld the district court’s ruling that the subject patent is invalid. On August 8, 2006, the Federal Circuit court upheld the District Court’s denial of attorneys’ fees. Neither side appealed the rulings by the Federal Circuit, and they are final.
In May 2006, the same company filed a state court lawsuit against us for malicious prosecution and abuse of process claiming that attorney’s fees, costs and other damages were due based on the outcome of a federal patent litigation suit brought against it by us. We do not believe this new action has merit, particularly given the denial by the federal court and the subsequent federal appellate court’s affirmation of the order denying the award of any attorney’s fees payable to this

20


Table of Contents

company by us in the federal patent litigation. We filed a motion to have the state court complaint dismissed under California’s anti-SLAPP and demurrer statutes. The state court granted the anti-SLAPP motion as to the abuse of process claim, but denied it as to the malicious prosecution claim. We have appealed the decision denying the anti-SLAPP motion as to the latter, and briefing thereon shall commence shortly.
On March 7, 2007, a shareholder filed a shareholder derivative lawsuit against us and certain of our current and former directors, officers and employees in the U.S. District Court for the Northern District of California. The lawsuit purports to be on behalf of Ultratech and asserts claims for violations of federal and state securities laws and for breach of fiduciary duty, unjust enrichment and other claims related to the alleged backdating of stock option grants between 1996 and 2003. On March 30, 2007, an essentially identical lawsuit was filed by another shareholder against us and certain of our current and former directors, officers and employees in the U.S. District Court for the Northern District of California. The complaints request an award of unspecified damages, an accounting of stock option grants, disgorgement of profits, rescission of option grants, equitable relief for alleged breach of fiduciary duty and awarding the plaintiff’s legal fees and expenses. As publicly reported in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2006, we proactively established a special committee of our Board of Directors comprised solely of independent directors to conduct a voluntary, company-initiated review of our historical stock option grants from Ultratech’s initial public offering in 1993 to July 2006. The special committee retained independent outside legal counsel to assist the committee with this review. The special committee completed its review and concluded there were no material accounting issues or backdating or other inappropriate manipulation regarding the issuance and pricing of stock options. Based on these findings, we have determined that no adjustments to previously filed financial statements are required.
Item 1A. Risk Factors
In addition to risks described in the foregoing discussions, the following risks apply to our business and us :
We currently spend, and expect to continue to spend, significant resources to develop, introduce and commercialize our laser processing systems and AP wafer stepper products, and we may not be successful in achieving or increasing sales of these products.
Currently, we are devoting significant resources to the development, introduction and commercialization of our laser products as well as our lithography wafer steppers. We intend to continue to develop these products and technologies during 2007, and will continue to incur significant operating expenses in the areas of research, development and engineering, manufacturing and general and administrative costs in order to develop, produce and support these new products. Additionally, gross profit margins and inventory levels may be further adversely impacted in the future by costs associated with the initial production of our laser processing systems and by future generations of our 1X lithography systems. Introduction of new products generally involves higher installation costs and product performance uncertainties that could delay customer acceptance of our systems, resulting in a delay in recognizing revenue associated with those systems and a reduction in gross margins. These costs include, but are not limited to, and additional manufacturing overhead, additional inventory write-downs, costs of demonstration systems and facilities, costs associated with the establishment of additional after-sales support organizations. Additionally, operating expenses may increase, relative to sales, as a result of adding additional marketing and administrative personnel, among other costs, to support our new products. If we are unable to achieve significantly increased net sales or if our sales fall below expectations, our operating results will be materially adversely affected.
Our ability to commercialize our laser processing technologies depends on our ability to demonstrate a manufacturing-worthy tool. We do not presently have in-house capability to fabricate devices. As a result, we must rely on partnering with semiconductor companies to develop the anneal process. The development of new process technologies is largely dependent upon our ability to interest potential customers in working on joint process development. Our ability to deliver timely solutions is also limited by wafer turnaround at the potential customer’s fabrication facility.
Our sales cycle is typically lengthy and involves a significant commitment of capital by our customers, which has subjected us, and is likely to continue to subject us, to delays in customer acceptances of our products and other risks, any of which could adversely impact our results of operations by, among other things, delaying recognition of revenue with respect to those orders and resulting in increased installation, qualification and similar costs.

21


Table of Contents

Sales of our systems depend, in significant part, upon the decision of a prospective customer to increase manufacturing capacity or to restructure current manufacturing facilities, either of which typically involves a significant commitment of capital. Many of our customers in the past have cancelled the development of new manufacturing facilities and have substantially reduced their capital equipment budgets. In view of the significant investment involved in a system purchase, we have experienced and may continue to experience delays following initial qualification of our systems as a result of delays in a customer’s approval process. Additionally, we are presently receiving orders for systems that have lengthy delivery schedules, which may be due to longer production lead times or a result of customers’ capacity scheduling requirements. For these and other reasons, our systems typically have a lengthy sales cycle during which we may expend substantial funds and management effort in securing a sale. Lengthy sales cycles subject us to a number of significant risks, including inventory obsolescence and fluctuations in operating results, over which we have little or no control. In order to maintain or exceed our present level of net sales, we are dependent upon obtaining orders for systems that will ship and be accepted in the current period. We may not be able to obtain those orders.
We may not be successful in protecting our intellectual property rights or we could be found to have infringed the intellectual property rights of others, either of which could weaken our competitive position and adversely affect our results of operations.
Although we attempt to protect our intellectual property rights through patents, copyrights, trade secrets and other measures, we believe that our success will depend more upon the innovation, technological expertise and marketing abilities of our employees. Nevertheless, we have a policy of seeking patents when appropriate on inventions resulting from our ongoing research and development and manufacturing activities. We own 119 United States and foreign patents, which expire on dates ranging from April 2008 to April 2025 and have 84 United States and foreign patent applications pending. In addition, we have various registered trademarks and copyright registrations covering mainly software programs used in the operation of our systems. We also rely upon trade secret protection for our confidential and proprietary information. We may not be able to protect our technology adequately and competitors may be able to develop similar technology independently. Our pending patent applications may not be issued or U.S. or foreign intellectual property laws may not protect our intellectual property rights. In addition, litigation may be necessary to enforce our patents, copyrights or other intellectual property rights, to protect our trade secrets, to determine the validity and scope of the proprietary rights of others or to defend against claims of infringement. Such litigation has resulted in, and in the future could result in, substantial costs and diversion of resources and could have a material adverse effect on our business, financial condition and results of operations, regardless of the outcome of the litigation. Patents issued to us may be challenged, invalidated or circumvented and the rights granted thereunder may not provide competitive advantages to us. Furthermore, others may independently develop similar technology or products, or, if patents are issued to us, design around the patents issued to us. Invalidation of our patents related to those technologies could allow our competitors to more effectively compete against us, which could result in less revenue for us.
On February 29, 2000, we filed lawsuits asserting patent infringement and related claims against Nikon, Canon and ASML in the U.S. District Court for the Eastern District of Virginia. In April 2000, we reached a settlement with Nikon, and in September 2001, we reached a settlement with Canon. In the patent litigation against ASML, after transfer to the U.S. District Court for the Northern District of California, a jury trial was conducted during the second quarter of 2005. The jury reached a verdict that the patent was infringed, but that the asserted claims of the patent were invalid. We filed a post-trial motion for a new trial and for judgment as a matter of law in our favor. ASML also filed a motion for judgment as a matter of law seeking to invalidate three of the asserted claims for lack of enablement and requested that the Court award costs. On February 13, 2006, the Court denied our post-trial motions, including the motion for a new trial, and entered judgment in favor of ASML invalidating three claims of the patent for lack of enablement. The Court also awarded ASML approximately $330,000 in costs. We have filed an appeal with the Federal Circuit Court of Appeals, and filed our opening appellate brief on August 31, 2006. Although ASML originally filed a notice of cross-appeal, ASML subsequently withdrew its cross appeal and the Court entered an order to that effect on December 8, 2006. ASML’s opening appellate brief was filed on December 6, 2006, and our reply brief was filed on January 12, 2007. The case is set for oral argument on May 11, 2007.
On July 11, 2003, we filed a lawsuit against a Southern California company asserting infringement of certain claims related to U.S. patent No. 5,621,813 in the U.S. District Court in and for the Northern District of California. On May 17, 2005, the court found the subject patent to be invalid. We appealed this decision. The defendant subsequently brought a motion for reimbursement of its attorneys’ fees and costs in a total asserted amount of approximately $2 million. We opposed this motion, and on October 12, 2005, the District Court denied the defendant’s request for attorneys’ fees in its entirety. The defendant appealed that decision. On November 3, 2005, the defendant filed a notice of appeal with respect to the court’s ruling on its motion for attorneys’ fees. In March 2006, the Federal Circuit court upheld the district court’s ruling that the

22


Table of Contents

subject patent is invalid. On August 8, 2006, the Federal Circuit court upheld the District Court’s denial of attorneys’ fees. Neither side appealed the rulings by the Federal Circuit, and they are final.
In May 2006, the same company filed a state court lawsuit against us for malicious prosecution and abuse of process claiming that attorney’s fees, costs and other damages were due based on the outcome of a federal patent litigation suit brought against it by us. We do not believe this new action has merit, particularly given the denial by the federal court and the subsequent federal appellate court’s affirmation of the order denying the award of any attorney’s fees payable to this company by us in the federal patent litigation. We filed a motion to have the state court complaint dismissed under California’s anti-SLAPP and demurrer statutes. The state court granted the anti-SLAPP motion as to the abuse of process claim, but denied it as to the malicious prosecution claim. We have appealed the decision denying the anti-SLAPP motion as to the latter, and briefing thereon shall commence shortly.
We believe that the outcome of these matters will not be material to our business, financial condition or results of operations.
We have from time to time been notified of claims that we may be infringing intellectual property rights possessed by third parties. We believe that the outcome of these matters will not be material to our business, results of operations or financial condition.
Infringement claims by third parties or claims for indemnification resulting from infringement claims may be asserted in the future and such assertions could materially adversely affect our business, financial condition and results of operations, regardless of the outcome of any litigation. With respect to any such future claims, we may seek to obtain a license under the third party’s intellectual property rights. However, a license may not be available on reasonable terms or at all. We could decide, in the alternative, to resort to litigation to challenge such claims. Such challenges could be expensive and time consuming and could materially adversely affect our business, financial condition and results of operations, regardless of the outcome of any litigation.
We operate in a highly competitive industry in which customers are required to invest substantial resources in each product, which makes it difficult to achieve significant sales to a particular customer once another vendor’s equipment has been purchased by that customer.
The capital equipment industry in which we operate is intensely competitive. A substantial investment is required to install and integrate capital equipment into a semiconductor, semiconductor packaging or nanotechnology device production line. We believe that once a device manufacturer or packaging subcontractor has selected a particular supplier’s capital equipment, the manufacturer generally relies upon that equipment for the specific production line application and, to the extent possible, subsequent generations of similar products. Accordingly, it is difficult to achieve significant sales to a particular customer once another supplier’s capital equipment has been selected.
We experience competition in advanced packaging from various proximity aligner companies such as Suss Microtec AG (Suss Microtec) and projection companies such as Ushio, Inc. (Ushio). In addition, some device manufacturers may consider using reduction steppers for advanced packaging processes. In nanotechnology, we experience competition from proximity aligner companies, such as Suss Microtec, as well as other stepper manufacturers who have developed or are developing tools specifically designed for nanotechnology applications. We expect our competitors in the lithography arena to continue to improve the performance of their current products and to introduce new products with improved price and performance characteristics. This could cause a decline in sales or loss of market acceptance of our steppers in our served markets, and thereby materially adversely affect our business, financial condition and results of operations. Enhancements to, or future generations of, competing products may be developed that offer superior cost of ownership and technical performance features.
With respect to our laser annealing technologies, marketed under the LSA100 product name, the primary competition comes from companies such as Applied Materials, Inc. and Dainippon Screen Manufacturing Co., LTD. Many of these companies offer products utilizing rapid thermal processing (RTP) which is the current prevailing manufacturing technology. RTP does not prevent semiconductor device manufacturers from scaling the lateral dimensions of their transistors to obtain improved performance, but diffusion resulting from the time scales associated with RTP limits the vertical dimension of the junctions. Faster annealing times result in shallower and more abrupt junctions and faster transistors. We believe that RTP manufacturers recognize the need to reduce thermal cycle times and are working toward this goal. In July 2000, we licensed certain rights to our then existing laser processing technology, with reservations, to a competing manufacturer of

23


Table of Contents

semiconductor equipment. We presently anticipate that this company will offer laser-annealing tools to the semiconductor industry that will compete with our offerings.
Another potential advanced annealing solution utilizes flash lamp annealing technology, or FLA. Several companies have published papers on annealing tools that incorporate flash lamp technology in order to reduce annealing times and increase anneal temperatures. Developers of FLA technology claim to have overcome annealing difficulties at the 65nm node. This technique, which employs xenon flash lamps, has shown improvements over RTP in junction depth and sheet resistance, but we believe FLA suffers from pattern-related non-uniformities and could require additional, costly processes to equalize the reflectivity of different areas within the chip or wafer. Our proprietary laser processing solution has been specifically developed to provide junction annealing on near-instantaneous time-scales, while achieving high activation levels. Laser spike annealing, the first implementation of laser processing, activates dopants in the microsecond-to-millisecond time frame without melting. Our research indicates that, at temperatures just below the melting point of silicon, time durations in the microsecond to millisecond range, are required to achieve full activation, and minimal dopant diffusion.
Additionally, competition to our laser processing products may come from other laser annealing tools, including those presently being used by the flat panel display industry to re-crystallize silicon. Manufacturers of these tools may try to extend the use of their technologies to semiconductor device applications.
We believe that in order to be competitive, we will need to continue to invest significant financial resources in new product development, new features and enhancements to existing products, the introduction of new stepper systems in our served markets on a timely basis, and maintaining customer service and support centers worldwide. In marketing our products, we may also face competition from vendors employing other technologies. In addition, increased competitive pressure has led to intensified price-based competition in certain of our markets, resulting in lower prices and margins. Should these competitive trends continue, our business, financial condition and operating results may be materially adversely affected.
We sell our products primarily to a limited number of customers and to customers in a limited number of industries, which subjects us to increased risks related to the business performance of our customers, and therefore their need for our products, and the business cycles of the markets into which we sell.
Historically, we have sold a substantial portion of our systems to a limited number of customers. In the first quarter of 2007, AMD, Fujitsu, Casio Micronics and United Microelectronics accounted for 31%, 24%, 19% and 17% of our system sales, respectively. In the first quarter of 2006, Texas Instruments, STATS ChipPAC and Micron accounted for 20%, 19% and 15%, of our total system sales, respectively. We expect that sales to a relatively few customers will continue to account for a high percentage of our net sales in the foreseeable future and believe that our financial results depend in significant part upon the success of these major customers and our ability to meet their future capital equipment needs. Although the composition of the group comprising our largest customers may vary from period to period, the loss of a significant customer or any reduction in orders by a significant customer, including reductions due to market, economic or competitive conditions in the semiconductor, semiconductor packaging or nanotechnology industries or in the industries that manufacture products utilizing integrated circuits, thin film heads or other nanotechnology components, would likely have a material adverse effect on our business, financial condition and results of operations. Our ability to maintain or increase our sales in the future depends, in part, on our ability to obtain orders from new customers as well as the financial condition and success of our existing customers, the semiconductor and nanotechnology industries and the economy in general.
In addition to the business risks associated with dependence on a few major customers, these significant customer concentrations have in the past resulted in significant concentrations of accounts receivable. These significant and concentrated receivables expose us to additional risks, including the risk of default by one or more customers representing a significant portion of our total receivables. If we were required to take additional accounts receivable reserves, our business, financial condition and results of operations would be materially adversely affected.
On a market application basis, sales to the semiconductor industry, primarily for advanced packaging applications and laser thermal processing, accounted for 95% of system revenue for each of the first quarters of 2007 and 2006. During each of the first quarters of 2007 and 2006, sales to nanotechnology manufacturers, including micro systems, thin film head and optical device manufacturers, accounted for the remaining 5% of our systems revenue. Our future operating results and financial condition would be materially adversely impacted by a downturn in any of these industries, or by loss of market share in any of these industries. A growing portion of our backlog of system orders is comprised of laser spike annealing tools. To date, we have limited customer experience with this technology. Should significant demand not materialize, due to technical,

24


Table of Contents

production, market, or other factors, our business, financial position and results of operations would be materially adversely impacted.
We rely on a limited number of outside suppliers and subcontractors to manufacture certain components and subassemblies, and on single or a limited group of outside suppliers for certain materials for our products, which could result in a potential inability to obtain an adequate supply of required components due to the suppliers’ failure or inability to provide such components in a timely manner, or at all, and reduced control over pricing and timely delivery of components and materials, any of which could adversely affect our results of operations.
Our manufacturing activities consist of assembling and testing components and subassemblies, which are then integrated into finished systems. We rely on a limited number of outside suppliers and subcontractors to manufacture certain components and subassemblies. We order one of the most critical components of our technology, the glass for our 1X lenses, from external suppliers. We design the 1X lenses and provide the lens specifications and the glass to other suppliers, who then grind and polish the lens elements. We then assemble and test the optical 1X lenses.
We procure some of our other critical systems’ components, subassemblies and services from single outside suppliers or a limited group of outside suppliers in order to ensure overall quality and timeliness of delivery. Many of these components and subassemblies have significant production lead times. To date, we have been able to obtain adequate services and supplies of components and subassemblies for our systems in a timely manner. However, disruption or termination of certain of these sources could have a significant adverse impact on our ability to manufacture our systems. This, in turn, would have a material adverse effect on our business, financial condition and results of operations. Our reliance on a sole supplier or a limited group of suppliers and our reliance on subcontractors involve several risks, including a potential inability to obtain an adequate supply of required components due to the suppliers’ failure or inability to provide such components in a timely manner, or at all, and reduced control over pricing and timely delivery of components. Although the timeliness, yield and quality of deliveries to date from our subcontractors have been acceptable, manufacture of certain of these components and subassemblies is an extremely complex process, and long lead-times are required. Any inability to obtain adequate deliveries or any other circumstance that would require us to seek alternative sources of supply or to manufacture such components internally could delay our ability to ship our products, which could damage relationships with current and prospective customers and have a material adverse effect on our business, financial condition and results of operations.
The semiconductor industry historically has been highly cyclical and has experienced periods of oversupply, which has in turn affected the market for semiconductor equipment such as ours and which can adversely affect our results of operations during such periods.
Our business depends in significant part upon capital expenditures by manufacturers of semiconductors, advanced packaging semiconductors and nanotechnology components, including thin film head magnetic recording devices, which in turn depend upon the current and anticipated market demand for such devices and products utilizing such devices. The semiconductor industry historically has been highly cyclical and has experienced recurring periods of oversupply. This has, from time to time, resulted in significantly reduced demand for capital equipment including the systems manufactured and marketed by us. We believe that markets for new generations of semiconductors and semiconductor packaging will also be subject to similar fluctuations. Our business and operating results would be materially adversely affected by downturns or slowdowns in the semiconductor packaging market or by loss of market share. Accordingly, we may not be able to achieve or maintain our current or prior level of sales. We attempt to mitigate the risk of cyclicality by participating in multiple markets including semiconductor, semiconductor packaging, and nanotechnology sectors, as well as diversifying into new markets such as laser-based annealing for implant activation and other applications. Despite such efforts, when one or more of such markets experiences a downturn or a situation of excess capacity, our net sales and operating results are materially adversely affected.
Our industry is subject to rapid technological change and product innovation, which could result in our technologies and products being replaced by those of our competitors, which would adversely affect our business and results of operations.
The semiconductor and nanotechnology manufacturing industries are subject to rapid technological change and new product introductions and enhancements. Our ability to be competitive in these and other markets will depend, in part, upon our ability to develop new and enhanced systems and related applications, and to introduce these systems and related applications at competitive prices and on a timely and cost-effective basis to enable customers to integrate them into their operations either prior to or as they begin volume product manufacturing. We will also be required to enhance the performance of our existing systems and related applications. Our success in developing new and enhanced systems and related applications

25


Table of Contents

depends upon a variety of factors, including product selection, timely and efficient completion of product design, timely and efficient implementation of manufacturing and assembly processes, product performance in the field and effective sales and marketing. Because new product development commitments must be made well in advance of sales, new product decisions must anticipate both future demand and the technology that will be available to meet that demand. We may not be successful in selecting, developing, manufacturing or marketing new products and related applications or enhancing our existing products and related applications. Any such failure would materially adversely affect our business, financial condition and results of operations.
Because of the large number of components in our systems, significant delays can occur between a system’s introduction and our commencement of volume production of such systems. We have experienced delays from time to time in the introduction of, and technical and manufacturing difficulties with, certain of our systems and enhancements and related software features and options, and may experience delays and technical and manufacturing difficulties in future introductions or volume production of new systems or enhancements and related software features and options.
We may encounter additional technical, manufacturing or other difficulties that could further delay future introductions or volume production of systems or enhancements. Our inability to complete the development or meet the technical specifications of any of our systems or enhancements and related applications, or our inability to manufacture and ship these systems or enhancements and related tools in volume and in time to meet the requirements for manufacturing the future generation of semiconductor or nanotechnology devices would materially adversely affect our business, financial condition and results of operations. In addition, we may incur substantial unanticipated costs to ensure the functionality and reliability of our products early in the products’ life cycles. If new products have reliability or quality problems, reduced orders or higher manufacturing costs, delays in customer acceptance, revenue recognition and collecting accounts receivable and additional service and warranty expenses may result. Any of such events may materially adversely affect our business, financial condition and results of operations.
A substantial portion of our sales are outside of the United States, which subjects us to risks related to customer service, installation, foreign economic and political stability, uncertain regulatory and tax rules, and foreign exchange rate fluctuations, all of which make it more difficult to operate our business.
International sales accounted for approximately 76% and 58% of total net sales for the first quarter of 2007 and 2006, respectively. We anticipate that international sales will continue to account for a significant portion of total net sales. As a result, a significant portion of our net sales will continue to be subject to certain risks, including unexpected changes in regulatory requirements; difficulty in satisfying existing regulatory requirements; exchange rate fluctuations; tariffs and other barriers; political and economic instability; difficulties in accounts receivable collections; natural disasters; difficulties in staffing and managing foreign subsidiary and branch operations; and potentially adverse tax consequences.
Although we generally transact our international sales in U.S. dollars, international sales expose us to a number of additional risk factors, including fluctuations in the value of local currencies relative to the U.S. dollar, which, in turn, impact the relative cost of ownership of our products and may further impact the purchasing ability of our international customers. However, in Japan, we have direct sales operations and orders are often denominated in Japanese yen. This may subject us to a higher degree of risk from currency fluctuations. We attempt to mitigate this exposure through the use of foreign currency forward exchange contracts. We are also subject to the risks associated with the imposition of legislation and regulations relating to the import or export of semiconductors and nanotechnology products. We cannot predict whether the United States or any other country will implement changes to quotas, duties, taxes or other charges or restrictions upon the importation or exportation of our products. These factors, or the adoption of restrictive policies, may have a material adverse effect on our business, financial condition and results of operations.
We are dependent on our key personnel, especially Mr. Zafiropoulo, our Chief Executive Officer, and our business and results of operations would be adversely affected if we were to lose our key employees.
Our future operating results depend, in significant part, upon the continued contributions of key personnel, many of whom would be difficult to replace. We have entered into employment agreements with only a limited number of our key employees, including our Chief Executive Officer and Chief Financial Officer, and our employees are employed “at will.” Some of these agreements contain vesting acceleration and severance payment provisions that could result in significant costs or charges to us should the employee be terminated without cause, die or have a disability. We do not maintain any life insurance on any of our key employees. The loss of key personnel could have a material adverse effect on our business,

26


Table of Contents

financial condition and results of operations. In addition, our future operating results depend in significant part upon our ability to attract and retain other qualified management, manufacturing, technical, sales and support personnel for our operations. There are only a limited number of persons with the requisite skills to serve in these positions and it may become increasingly difficult for us to hire such personnel over time. At times, competition for such personnel has been intense, particularly in the San Francisco Bay Area, where we maintain our headquarters and principal operations, and we may not be successful in attracting or retaining such personnel. The failure to attract or retain such persons would materially adversely affect our business, financial condition and results of operations.
Changes in financial accounting standards or policies in the past have affected, and in the future may, affect, our reported results of operations.
We prepare our financial statements in conformity with accounting principles generally accepted in the United States (U.S. GAAP). These principles are subject to interpretation by the Financial Accounting Standards Board (FASB), the American Institute of Certified Public Accountants (AICPA), the Securities and Exchange Commission (SEC) and various bodies formed to interpret and create appropriate accounting policies. A change in those policies can have a significant effect on our reported results and may affect our reporting of transactions which are completed before a change is announced.
Accounting policies affecting many other aspects of our business, including rules relating to revenue recognition, off-balance sheet transactions, employee stock options, restructurings, asset disposals and asset retirement obligations, intangible assets, derivative and other financial instruments, and in-process research and development charges, have recently been revised or are under review. Changes to those rules or the questioning of how we interpret or implement those rules may have a material adverse effect on our reported financial results or on the way we conduct business. In addition, our preparation of financial statements in accordance with U.S. GAAP requires that we make estimates and assumptions that affect the recorded amounts of assets and liabilities, disclosure of those assets and liabilities at the date of the financial statements and the recorded amounts of expenses during the reporting period. A change in the facts and circumstances surrounding those estimates could result in a change to our estimates and could impact our future operating results.
Changes in securities laws and listing standards, in particular those that have resulted from the passage of the Sarbanes-Oxley Act of 2002 and related rules and regulations, have increased our legal and financial costs, and we expect to continue to spend significant resources to comply with these requirements.
The Sarbanes-Oxley Act of 2002 required changes in our corporate governance, public disclosure and compliance practices. The number of rules and regulations applicable to us have increased and will continue to increase our legal and financial compliance costs, and have made some activities more difficult, such as by requiring stockholder approval of new option plans. In addition, we have incurred and expect to continue to incur significant costs in connection with compliance with Section 404 of the Sarbanes-Oxley Act regarding internal controls over financial reporting. We incurred significant costs to achieve initial compliance with Section 404, and we expect ongoing annual costs to maintain compliance to also be substantial. We also expect these developments to make it more difficult and more expensive to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These developments could make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee, and qualified executive officers. In addition, in connection with our Section 404 certification process, we may identify from time to time deficiencies in our internal controls. Any material weakness or deficiency in our internal controls over financial reporting could materially and negatively impact our reported financial results and the market price of our stock could significantly decline. Additionally, adverse publicity related to the disclosure of a material weakness or deficiency in internal controls over financial reporting could have a negative impact on our reputation, business and stock price.
Our equity incentive plans, certain provisions of our Certificate of Incorporation and Bylaws, and Delaware law may discourage third parties from pursuing a change of control transaction with us.
Certain provisions of our Certificate of Incorporation, equity incentive plans, licensing agreements, Bylaws and Delaware law may discourage certain transactions involving a change in control of our company. In addition to the foregoing, our classified board of directors, the shareholdings of our officers, directors and persons or entities that may be deemed affiliates and the ability of the Board of Directors to issue “blank check” preferred stock without further stockholder approval could have the effect of delaying, deferring or preventing us from experiencing a change in control and may adversely affect the voting and other rights of holders of our Common Stock.

27


Table of Contents

Our stock price has experienced significant volatility in the past and we expect this to continue in the future as a result of many factors, some of which could be unrelated to our operating performance, and such volatility can have a major impact on the number of shares subject to outstanding stock options that are included in calculating our earnings per share.
We believe that factors such as announcements of developments related to our business, fluctuations in our operating results, a shortfall in revenue or earnings, changes in analysts’ expectations, general conditions in the semiconductor and nanotechnology industries or the worldwide or regional economies, sales of our securities into the marketplace, an outbreak or escalation of hostilities, announcements of technological innovations or new products or enhancements by us or our competitors, developments in patents or other intellectual property rights and developments in our relationships with our customers and suppliers could cause the price of our Common Stock to fluctuate, perhaps substantially. The market price of our Common Stock has fluctuated significantly in the past and we expect it to continue to experience significant fluctuations in the future, including fluctuations that may be unrelated to our performance.
As of March 31, 2007, we had options to purchase approximately 5.7 million shares of our Common Stock outstanding. Among other determinants, the market price of our stock has a major bearing on the number of shares subject to outstanding stock options that are included in the weighted-average shares used in determining our net income (loss) per share. During periods of extreme volatility, the impact of higher stock prices can have a materially dilutive effect on our net income (loss) per share. Additionally, shares subject to outstanding options are excluded from the calculation of net income (loss) per share when we have a net loss or when the exercise price of the stock option is greater than the average market price of our Common Stock, as the impact of the stock options would be anti-dilutive.
Our results of operations and business could be adversely affected by wars and other military action, as well as terrorist attacks and threats and government responses thereto, especially if any such actions were directed at us or our facilities or customers.
Terrorist attacks in the United States and elsewhere, government responses thereto, and military actions in Iraq, Afghanistan and elsewhere, may disrupt our operations or those of our customers and suppliers and may affect the availability of materials needed to manufacture our products or the means to transport those materials to manufacturing facilities and finished products to customers. In addition, any of these events could increase volatility in the United States and world financial markets which may depress the price of our Common Stock and may limit the capital resources available to us or our customers or suppliers, which could result in decreased orders from customers, less favorable financing terms from suppliers, and scarcity or increased costs of materials and components of our products. Additionally, terrorist attacks directly upon us may significantly disrupt our ability to conduct our business. Any of these occurrences could have a significant impact on our operating results, revenues and costs and may result in increased volatility of the market price of our Common Stock.
If we acquire companies, products, or technologies, we may face risks associated with those acquisitions.
In July 2006 we purchased certain assets of Oraxion, Inc. Oraxion produced inspection equipment for surface metrology and stress analysis for the semiconductor industry. We may not realize the anticipated benefits of any acquisition or investment. We may in the future pursue additional acquisitions of complementary product lines, technologies or businesses. Future acquisitions may result in potentially dilutive issuances of equity securities, the incurrence of debt and contingent liabilities and amortization expenses and impairment charges related to goodwill and other intangible assets, which could materially adversely affect our financial condition and results of operations. In addition, acquisitions involve numerous risks, including difficulties in the assimilation of the operations, technologies, personnel and products of the acquired companies; the diversion of management’s attention from other business concerns; risks of entering markets in which we have limited or no direct experience; and the potential loss of key employees of the acquired company. In the event we acquire product lines, technologies or businesses which do not complement our business, or which otherwise do not enhance our sales or operating results, we may incur substantial write-offs and higher recurring operating costs, which could have a material adverse effect on our business, financial condition and results of operations. In the event that any such acquisition does occur, there can be no assurance as to the effect thereof on our business or operating results.
Our long-term expenses reduction programs may result in an increase in short-term expenses.
In the first quarter of 2007, as a continuing effort to reduce company-wide expenses since the fourth quarter of 2006, we eliminated an additional 26 full-time positions, 85% in the United States and 15% internationally. Pursuant to the provisions

28


Table of Contents

of FASB Statement No. 146, Accounting for Costs Associated with Exit or Disposal Activities , during the first quarter of 2007, we recorded severance and benefits charges totaling $0.7 million related this plan. Out of this $0.7 million, $0.4 million was recorded as selling, general and administrative expenses, $0.2 million as cost of sales, and the remaining $0.1 million as research, development, and engineering expenses. As of March 31, 2007, the remaining balances of $0.6 million and $0.2 million related to severance and benefit payments incurred during the fourth quarter of 2006 and the first quarter of 2007, respectively, will be fully paid by the second quarter of 2008.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
In September 2005 that our Board of Directors authorized the repurchase of up to $30.0 million of our common stock in the open market during the period commencing September 2005 through September 2007. We purchased a total of 1.4 million shares of our common stock since September 2005 for a total of $20.0 million. However, we did not repurchase any shares of our common stock during the three months ended March 31, 2007.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Submission of Matters to a Vote of Security Holders.
None.
Item 5. Other Information.
None.
Item 6. Exhibits
10.1   Amendment to Employment Agreement between Registrant and Mr. Rick Friedman, Former Senior Vice President World-wide Sales and Customer Service, incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on January 9, 2007.
 
10.2   Separation and General Release Agreement between Registrant and Mr. Rick Friedman, Former Senior Vice President World-wide Sales and Customer Service, incorporated herein by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the Commission on January 9, 2007.
 
10.3   Amended and Restated Employment Agreement between Registrant and Mr. Bruce Wright, Chief Financial Officer, incorporated herein by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed with the Commission on January 9, 2007.
 
10.4   2007 Management Incentive Compensation Plan Description, incorporated herein by reference to Item 5.02 of the Registrant’s Current Report on Form 8-K filed with the Commission on February 2, 2007.
 
31.1   Certification of Chief Executive Officer required pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
31.2   Certification of Chief Financial Officer required pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
32.1   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

29


Table of Contents

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
         
    ULTRATECH, INC.
    (Registrant)
 
       
Date: April 30, 2007
  By:   /s/ BRUCE WRIGHT
 
       
 
      Bruce Wright
 
      Senior Vice President, Finance and Chief Financial
 
      Officer (Duly Authorized Officer and Principal
 
      Financial and Accounting Officer)

30


Table of Contents

EXHIBIT INDEX
10.1   Amendment to Employment Agreement between Registrant and Mr. Rick Friedman, Former Senior Vice President World-wide Sales and Customer Service, incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on January 9, 2007.
 
10.2   Separation and General Release Agreement between Registrant and Mr. Rick Friedman, Former Senior Vice President World-wide Sales and Customer Service, incorporated herein by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the Commission on January 9, 2007.
 
10.3   Amended and Restated Employment Agreement between Registrant and Mr. Bruce Wright, Chief Financial Officer, incorporated herein by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed with the Commission on January 9, 2007.
 
10.4   2007 Management Incentive Compensation Plan Description, incorporated herein by reference to Item 5.02 of the Registrant’s Current Report on Form 8-K filed with the Commission on February 2, 2007.
 
31.1   Certification of Chief Executive Officer required pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
31.2   Certification of Chief Financial Officer required pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
32.1   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 


 

Exhibit 31.1
     I, Arthur Zafiropoulo, certify that:
     1. I have reviewed this quarterly report on Form 10-Q of Ultratech, Inc.;
     2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
     a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
     
Date: April 30, 2007
  /s/ ARTHUR ZAFIROPOULO
 
   
 
  Arthur Zafiropoulo
 
  Chief Executive Officer

 


 

Exhibit 31.2
     I, Bruce Wright, certify that:
     1. I have reviewed this quarterly report on Form 10-Q of Ultratech, Inc.;
     2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
     a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
     
Date: April 30, 2007
  /s/ BRUCE WRIGHT
 
   
 
  Bruce Wright
 
  Chief Financial Officer

 


 

Exhibit 32.1
CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
     I, Arthur Zafiropoulo, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
    the Quarterly Report of Ultratech, Inc. on Form 10-Q for the period ended March 31, 2007 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
    the information contained in such Quarterly Report fairly presents in all material respects the financial condition and results of operations of Ultratech, Inc.
             
By:
  /s/ ARTHUR ZAFIROPOULO       Date: April 30, 2007
             
Name:
  Arthur Zafiropoulo        
Title:
  Chief Executive Officer        
     I, Bruce Wright, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
    the Quarterly Report of Ultratech, Inc. on Form 10-Q for the period ended March 31, 2007 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
    the information contained in such Quarterly Report fairly presents in all material respects the financial condition and results of operations of Ultratech, Inc.
             
By:
  /s/ BRUCE WRIGHT       Date: April 30, 2007
             
Name:
  Bruce Wright        
Title:
  Chief Financial Officer        
 
*   A signed original of this written statement required by Section 906 has been provided to Ultratech, Inc. and will be retained by Ultratech, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.